Applicability of Histoculture Drug Response Assays in Colorectal Cancer Chemotherapy

The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven co...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 32; no. 8; pp. 3581 - 3586
Main Authors YOON, Yongsik, CHANWOOKKIM, SEONAEROH, HYUNGCHO, Dong, GYUPYOKIM, YONG SANG HONG, TAE WON KIM, MOON BO KIM, JIN CHEON KIM
Format Journal Article
LanguageEnglish
Published Attiki International Institute of Anticancer Research 01.08.2012
Subjects
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Colorectal Neoplasms - drug therapy
Drug Screening Assays, Antitumor
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Middle Aged
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumor Cells, Cultured
Tumors
Drug
Rectal disease
Prognosis
Targeted therapy
Colorectal adenocarcinomas
Colorectal adenocarcinoma
Colorectal cancer
Malignant tumor
treatment outcome
Colonic disease
Chemotherapy
Cancerology
Treatment
Digestive diseases
Intestinal disease
molecular targeted therapy
Cancer
histoculture drug response assay (HDRA)
Online AccessGet full text

Cover

More Information
Summary:The present study, using the histoculture drug response assay (HDRA) compared chemosensitivity with the clinical response of a treatment regime in patients with advanced colorectal cancer (CRC). A total of 324 patients with primary CRC were prospectively enrolled. HDRAs were performed using seven combinations of anticancer drugs, including 5-fluorouracil with leucovorin (FL), FL with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and their combinations with bevacizumab and cetuximab. Among 324 HDRA results, tumor inhibition rates of regimes using FOLFOX (34.2-39.2%) were higher than those using FOLFIRI (24.2-32.7%, p<0.001). Out of 86 evaluated chemotherapeutic regimes, the correlation rate of HDRA to the clinical effect of chemotherapy was calculated to be 66.3% (57/86), with a 72.7% (40/55) sensitivity and a 54.7% (17/31) specificity. HDRA might be a feasible and useful technique for predicting therapy efficacy and selecting the appropriate anticancer regime for individual patients, notwithstanding its low accuracy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0250-7005
1791-7530